With only 5 weeks to go, the 80+ attendee list for the upcoming mRNA Process Development and Manufacturing Summit Europe (April 18th – 20th | Frankfurt, Germany) is still growing fast, further demonstrating biopharma’s desire to explore the major challenges of scalable mRNA drug substance, capping, purification, and the regulatory landscape to develop their manufacturing process and commercialisation
|
AstraZeneca Bayer AG x3 BioMerieux Sweden AB x2 Bion Environmental Technologies BioNTech SE x4 BioSpring GmbH x3 CanSino Biologics Inc. CureVac x2 EnginZyme Eurocine Vaccines AB ExploRNA Therapeutics Genentech GSK x4 Inofea AG |
Johnson & Johnson x2 Lonza Merck KGaA x7 Novartis AG Primordial Genetics Quantoom Biosciences Repligen Corporation Roche x3 Sanofi Pasteur x2 Takara Bio Theragen Bio Thermo Fisher Scientific TriLink WuXi Biologics |
Make sure you download the brochure to find out more about this industry leading speaker faculty and their talks: https://ter.li/jy47at